The improved health utility of once-weekly subcutaneous semaglutide [amount hidden] compared with placebo in the STEP 1-4 obesity trials

What Was Tested

Researchers studied Semaglutide in this randomized controlled trial publication.

To assess health utility values in the Semaglutide Treatment Effect in People with obesity (STEP) 1-4 trials.

Who Took Part

Patients received lifestyle intervention plus intensive behavioural therapy in STEP 3.

Scores were converted into Short Form Six-Dimension version 2 (SF-6Dv2) utility scores or mapped onto the European Quality of Life Five-Dimension Three-Level (EQ-5D-3L) utility index using UK health utility weights.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Because people in this Semaglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Semaglutide.

The comparison arm used a placebo, so changes seen with Semaglutide could be set against what happens without it.

Health-related quality of life was assessed using the Short Form 36-item Health Survey version 2 (SF-36v2) at baseline and week 68.

What Was Measured

PubMed files the paper under topics including Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Hypoglycemic Agents, Obesity, Quality of Life and Semaglutide.

The authors tagged it with the keywords antiobesity drug, patient-reported outcomes and randomized trial.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Semaglutide.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2023 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Semaglutide compound page, all human trials.